ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

Contributed by: GlobeNewswire

Tags

obesity

More Like This

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1

First GLP-1 tablet for weight loss approved in the UK

PR Newswire associated0

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

Camurus reports positive topline results for CAM2056, semaglutide monthly depot

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

PR Newswire associated0

Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

PR Newswire associated0

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors